R0278
RIPA Buffer
Synonym(s):
Radioimmunoprecipitation assay buffer
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
description
protease free
Quality Level
form
liquid
packaging
pkg of 50 mL
pkg of 500 mL
technique(s)
immunoprecipitation (IP): suitable
color
colorless
pH
7.8-8.2 (25 °C, 1 ×)
storage temp.
2-8°C
Looking for similar products? Visit Product Comparison Guide
General description
RIPA (Radio-Immunoprecipitation Assay) Buffer is supplied as a ready to use solution that requires no preparation. It minimizes non-specific protein-binding interactions to keep background low, while allowing most specific interactions to occur, enabling studies of relevant protein-protein interactions. It is widely used in applications such as immunoprecipitation since most antibodies and protein antigens are not adversely affected by the components of this buffer.
Radioimmunoprecipitation assay buffer (RIPA buffer) is a lysis buffer used for rapid, efficient cell lysis and solubilization of proteins from both adherent and suspension cultured mammalian cells.
Application
RIPA Buffer has been used as a reagent for cell lysis in the following experimental studies:
- Fibroblast-based deep phenotyping of the peripheral tissue, which facilitates the mechanistic disease stratification in sporadic Parkinson′s disease (sPD).
- Demonstrating the inhibition of oxidative phosphorylation (OXPHOS), which can activate the mixed lineage kinase domain-like protein (MLKL)-dependent necroptosis in human lung epithelial cells.
RIPA Buffer enables efficient cell lysis and protein solubilization while avoiding protein degradation and interference with the proteins′ immunoreactivity and biological activity. RIPA Buffer also results in low background in immunoprecipitation and molecular pull-down assays. Compatible with EZview™ Affinity Gels.
Features and Benefits
1 mL of the RIPA Buffer is used to lyse cells from one 100 mm culture dish (0.5 to 5 * 107 cells) of most adherent mammalian cell lines.
Minimizes non-specific protein binding interactions to ensure low background.
Other Notes
Ready-to-use solution containing 150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0.
Legal Information
EZview is a trademark of Sigma-Aldrich Co. LLC
IGEPAL is a registered trademark of Solvay
also commonly purchased with this product
Product No.
Description
Pricing
related product
Product No.
Description
Pricing
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Aquatic Chronic 3 - Eye Irrit. 2
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Elham Abbasloo et al.
Neuropeptides, 60, 7-12 (2016-08-21)
Pain represents a major contributing factor to the individual's quality of life. Although pain killers as opioids, endogenous or exogenous peptides can decrease pain perception, the chronic use of them leads to antinociceptive tolerance. It has been demonstrated that neuropeptide
Paula Kinsella et al.
Investigational new drugs, 34(2), 159-167 (2016-02-18)
The C-KIT receptor tyrosine kinase is constitutively activated in the majority of gastrointestinal stromal tumours (GIST). Imatinib (IM) a selective inhibitor of C-KIT, is indicated for the treatment of KIT-positive unresectable and/or metastatic GIST, and has tripled the survival time
Impaired oxidative phosphorylation regulates necroptosis in human lung epithelial cells
Koo MJ, et al.
Biochemical and Biophysical Research Communications, 464(3), 875-880 (2015)
Zuzana Keckesova et al.
Nature, 543(7647), 681-686 (2017-03-23)
Post-mitotic, differentiated cells exhibit a variety of characteristics that contrast with those of actively growing neoplastic cells, such as the expression of cell-cycle inhibitors and differentiation factors. We hypothesized that the gene expression profiles of these differentiated cells could reveal
Hartmut Jahns et al.
Nature communications, 6, 6317-6317 (2015-03-07)
An established means of improving the pharmacokinetics properties of oligoribonucleotides (ORNs) is to exchange their phosphodiester linkages for phosphorothioates (PSs). However, this strategy has not been pursued for small interfering RNAs (siRNAs), possibly because of sporadic reports that PS siRNAs
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service